Inhibition of c-Jun NH2-terminal kinase stimulates mu opioid receptor expression via p38 MAPK-mediated nuclear NF-κB activation in neuronal and non-neuronal cells

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1833, Issue 6, 2013, Pages 1476-1488

  Wagley, Yadav ^a   Hwang, Cheol Kyu ^a   Lin, Hong Yiou ^a   Kam, Angel F Y ^a   Law, Ping Yee ^a   Loh, Horace H ^a   Wei, Li Na ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

JNK; MAPK; Mu opioid receptor; NF B

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MU OPIATE RECEPTOR; SMALL INTERFERING RNA;

ARTICLE; CELL NUCLEUS; CHROMATIN IMMUNOPRECIPITATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOSOL; ENZYME BINDING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; UPREGULATION;

ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; CHROMATIN IMMUNOPRECIPITATION; EMBRYONAL CARCINOMA STEM CELLS; IMMUNOPRECIPITATION; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; NEURONS; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, OPIOID, MU; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 84875798451     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2013.02.017     Document Type: Article

References (60)

1. Wei L.N., Loh H.H. Transcriptional and epigenetic regulation of opioid receptor genes: present and future. Annu. Rev. Pharmacol. Toxicol. 2011, 51:75-97.
2. Law P.Y., Loh H.H., Wei L.N. Insights into the receptor transcription and signaling: implications in opioid tolerance and dependence. Neuropharmacology 2004, 47(Suppl. 1):300-311.
3. Sora I., Takahashi N., Funada M., Ujike H., Revay R.S., Donovan D.M., Miner L.L., Uhl G.R. Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:1544-1549.
4. Ikeda K., Kobayashi T., Ichikawa T., Kumanishi T., Niki H., Yano R. The untranslated region of (mu)-opioid receptor mRNA contributes to reduced opioid sensitivity in CXBK mice. J. Neurosci. 2001, 21:1334-1339.
5. Loh H.H., Liu H.C., Cavalli A., Yang W., Chen Y.F., Wei L.N. mu Opioid receptor knockout in mice: effects on ligand-induced analgesia and morphine lethality. Brain Res. Mol. Brain Res. 1998, 54:321-326.
6. Ko J.L., Minnerath S.R., Loh H.H. Dual promoters of mouse mu-opioid receptor gene. Biochem. Biophys. Res. Commun. 1997, 234:351-357.
7. Liang Y., Carr L.G. Identification of an octamer-1 transcription factor binding site in the promoter of the mouse mu-opioid receptor gene. J. Neurochem. 1996, 67:1352-1359.
8. Kraus J., Borner C., Giannini E., Hickfang K., Braun H., Mayer P., Hoehe M.R., Ambrosch A., Konig W., Hollt V. Regulation of mu-opioid receptor gene transcription by interleukin-4 and influence of an allelic variation within a STAT6 transcription factor binding site. J. Biol. Chem. 2001, 276:43901-43908.
9. Im H.J., Smirnov D., Yuhi T., Raghavan S., Olsson J.E., Muscat G.E., Koopman P., Loh H.H. Transcriptional modulation of mouse mu-opioid receptor distal promoter activity by Sox18. Mol. Pharmacol. 2001, 59:1486-1496.
10. Hwang C.K., Wu X., Wang G., Kim C.S., Loh H.H. Mouse mu opioid receptor distal promoter transcriptional regulation by SOX proteins. J. Biol. Chem. 2003, 278:3742-3750.
11. Choe C., Im H.J., Ko J.L., Loh H.H. Mouse mu opioid receptor gene expression. A 34-base pair cis-acting element inhibits transcription of the mu opioid receptor gene from the distal promoter. J. Biol. Chem. 1998, 273:34926-34932.
12. Xu Y., Carr L.G. Functional characterization of the promoter region of the human mu opioid receptor (hMOR) gene: identification of activating and inhibitory regions. Cell. Mol. Biol. 2001, ((Noisy-le-grand) 47 Online Pub (2001) OL29-38).
13. Kim S.S., Pandey K.K., Choi H.S., Kim S.Y., Law P.Y., Wei L.N., Loh H.H. Poly(C) binding protein family is a transcription factor in mu-opioid receptor gene expression. Mol. Pharmacol. 2005, 68:729-736.
14. Ko J.L., Liu H.C., Minnerath S.R., Loh H.H. Transcriptional regulation of mouse mu-opioid receptor gene. J. Biol. Chem. 1998, 273:27678-27685.
15. Ko J.L., Liu H.C., Loh H.H. Role of an AP-2-like element in transcriptional regulation of mouse mu-opioid receptor gene. Brain Res. Mol. Brain Res. 2003, 112:153-162.
16. Ko J.L., Loh H.H. Single-stranded DNA-binding complex involved in transcriptional regulation of mouse mu-opioid receptor gene. J. Biol. Chem. 2001, 276:788-795.
17. Li H., Liu H., Wang Z., Liu X., Guo L., Huang L., Gao L., McNutt M.A., Li G. The role of transcription factors Sp1 and YY1 in proximal promoter region in initiation of transcription of the mu opioid receptor gene in human lymphocytes. J. Cell. Biochem. 2008, 104:237-250.
18. Kraus J., Borner C., Giannini E., Hollt V. The role of nuclear factor kappaB in tumor necrosis factor-regulated transcription of the human mu-opioid receptor gene. Mol. Pharmacol. 2003, 64:876-884.
19. Lee P.W., Lee Y.M. Transcriptional regulation of mu opioid receptor gene by cAMP pathway. Mol. Pharmacol. 2003, 64:1410-1418.
20. Kim D.K., Hwang C.K., Wagley Y., Law P.Y., Wei L.N., Loh H.H. p38 Mitogen-activated protein kinase and PI3-kinase are involved in up-regulation of mu opioid receptor transcription induced by cycloheximide. J. Neurochem. 2011, 116:1077-1087.
21. Gao Y.J., Ji R.R. Activation of JNK pathway in persistent pain. Neurosci. Lett. 2008, 437:180-183.
22. Bogoyevitch M.A., Ngoei K.R., Zhao T.T., Yeap Y.Y., Ng D.C. c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges. Biochim. Biophys. Acta 2010, 1804:463-475.
23. Renlund N., Pieretti-Vanmarcke R., O'Neill F.H., Zhang L., Donahoe P.K., Teixeira J. c-Jun N-terminal kinase inhibitor II (SP600125) activates Mullerian inhibiting substance type II receptor-mediated signal transduction. Endocrinology 2008, 149:108-115.
24. Kam A.Y., Chan A.S., Wong Y.H. Phosphatidylinositol-3 kinase is distinctively required for mu-, but not kappa-opioid receptor-induced activation of c-Jun N-terminal kinase. J. Neurochem. 2004, 89:391-402.
25. Lin X., Wang Y.J., Li Q., Hou Y.Y., Hong M.H., Cao Y.L., Chi Z.Q., Liu J.G. Chronic high-dose morphine treatment promotes SH-SY5Y cell apoptosis via c-Jun N-terminal kinase-mediated activation of mitochondria-dependent pathway. FEBS J. 2009, 276:2022-2036.
26. Singhal P., Kapasi A., Reddy K., Franki N. Opiates promote T cell apoptosis through JNK and caspase pathway. Adv. Exp. Med. Biol. 2001, 493:127-135.
27. Guo R.X., Zhang M., Liu W., Zhao C.M., Cui Y., Wang C.H., Feng J.Q., Chen P.X. NMDA receptors are involved in upstream of the spinal JNK activation in morphine antinociceptive tolerance. Neurosci. Lett. 2009, 467:95-99.
28. Fan X.L., Zhang J.S., Zhang X.Q., Ma L. Chronic morphine treatment and withdrawal induce up-regulation of c-Jun N-terminal kinase 3 gene expression in rat brain. Neuroscience 2003, 122:997-1002.
29. Melief E.J., Miyatake M., Bruchas M.R., Chavkin C. Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:11608-11613.
30. Zhuang Z.Y., Wen Y.R., Zhang D.R., Borsello T., Bonny C., Strichartz G.R., Decosterd I., Ji R.R. A peptide c-Jun N-terminal kinase (JNK) inhibitor blocks mechanical allodynia after spinal nerve ligation: respective roles of JNK activation in primary sensory neurons and spinal astrocytes for neuropathic pain development and maintenance. J. Neurosci. 2006, 26:3551-3560.
31. Gao Y.J., Cheng J.K., Zeng Q., Xu Z.Z., Decosterd I., Xu X., Ji R.R. Selective inhibition of JNK with a peptide inhibitor attenuates pain hypersensitivity and tumor growth in a mouse skin cancer pain model. Exp. Neurol. 2009, 219:146-155.
32. Hwang C.K., Song K.Y., Kim C.S., Choi H.S., Guo X.H., Law P.Y., Wei L.N., Loh H.H. Evidence of endogenous mu opioid receptor regulation by epigenetic control of the promoters. Mol. Cell. Biol. 2007, 27:4720-4736.
33. Hwang C.K., Kim C.S., Kim do K., Law P.Y., Wei L.N., Loh H.H. Up-regulation of the mu-opioid receptor gene is mediated through chromatin remodeling and transcriptional factors in differentiated neuronal cells. Mol. Pharmacol. 2010, 78:58-68.
34. Kim C.S., Hwang C.K., Choi H.S., Song K.Y., Law P.Y., Wei L.N., Loh H.H. Neuron-restrictive silencer factor (NRSF) functions as a repressor in neuronal cells to regulate the mu opioid receptor gene. J. Biol. Chem. 2004, 279:46464-46473.
35. Kim J.A., Lee J., Margolis R.L., Fotedar R. SP600125 suppresses Cdk1 and induces endoreplication directly from G2 phase, independent of JNK inhibition. Oncogene 2010, 29:1702-1716.
36. Nakaya K., Ooishi R., Funaba M., Murakami M. A JNK inhibitor SP600125 induces defective cytokinesis and enlargement in P19 embryonal carcinoma cells. Cell Biochem. Funct. 2009, 27:468-472.
37. Vaishnav D., Jambal P., Reusch J.E., Pugazhenthi S. SP600125, an inhibitor of c-jun N-terminal kinase, activates CREB by a p38 MAPK-mediated pathway. Biochem. Biophys. Res. Commun. 2003, 307:855-860.
38. Moon D.O., Choi Y.H., Kim G.Y. Role of p21 in SP600125-induced cell cycle arrest, endoreduplication, and apoptosis. Cell. Mol. Life Sci. 2011, 68:3249-3260.
39. Yeste-Velasco M., Folch J., Casadesus G., Smith M.A., Pallas M., Camins A. Neuroprotection by c-Jun NH2-terminal kinase inhibitor SP600125 against potassium deprivation-induced apoptosis involves the Akt pathway and inhibition of cell cycle reentry. Neuroscience 2009, 159:1135-1147.
40. Andria M.L., Simon E.J. Identification of a neurorestrictive suppressor element (NRSE) in the human mu-opioid receptor gene. Brain Res. Mol. Brain Res. 2001, 91:73-80.
41. Liu S., Chen Z.J. Expanding role of ubiquitination in NF-kappaB signaling. Cell Res. 2011, 21:6-21.
42. Reber L., Vermeulen L., Haegeman G., Frossard N. Ser276 phosphorylation of NF-kB p65 by MSK1 controls SCF expression in inflammation. PLoS One 2009, 4:e4393.
43. Chen H.C., Wei L.N., Loh H.H. Expression of mu-, kappa- and delta-opioid receptors in P19 mouse embryonal carcinoma cells. Neuroscience 1999, 92:1143-1155.
44. Chen H.C., Loh H.H. mu-Opioid receptor gene expression: the role of NCAM. Neuroscience 2001, 108:7-15.
45. Okamoto S., Krainc D., Sherman K., Lipton S.A. Antiapoptotic role of the p38 mitogen-activated protein kinase-myocyte enhancer factor 2 transcription factor pathway during neuronal differentiation. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:7561-7566.
46. Reffas S., Schlegel W. Compartment-specific regulation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) mitogen-activated protein kinases (MAPKs) by ERK-dependent and non-ERK-dependent inductions of MAPK phosphatase (MKP)-3 and MKP-1 in differentiating P19 cells. Biochem. J. 2000, 352(Pt 3):701-708.
47. Oh J.E., Bae G.U., Yang Y.J., Yi M.J., Lee H.J., Kim B.G., Krauss R.S., Kang J.S. Cdo promotes neuronal differentiation via activation of the p38 mitogen-activated protein kinase pathway. FASEB J. 2009, 23:2088-2099.
48. Yamdeu R.S., Shaqura M., Mousa S.A., Schafer M., Droese J. p38 Mitogen-activated protein kinase activation by nerve growth factor in primary sensory neurons upregulates mu-opioid receptors to enhance opioid responsiveness toward better pain control. Anesthesiology 2011, 114:150-161.
49. Wagner E.F., Nebreda A.R. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat. Rev. Cancer 2009, 9:537-549.
50. Muniyappa H., Das K.C. Activation of c-Jun N-terminal kinase (JNK) by widely used specific p38 MAPK inhibitors SB202190 and SB203580: a MLK-3-MKK7-dependent mechanism. Cell. Signal. 2008, 20:675-683.
51. Kumar S., Jiang M.S., Adams J.L., Lee J.C. Pyridinylimidazole compound SB 203580 inhibits the activity but not the activation of p38 mitogen-activated protein kinase. Biochem. Biophys. Res. Commun. 1999, 263:825-831.
52. Hideshima T., Hayashi T., Chauhan D., Akiyama M., Richardson P., Anderson K. Biologic sequelae of c-Jun NH(2)-terminal kinase (JNK) activation in multiple myeloma cell lines. Oncogene 2003, 22:8797-8801.
53. Madrid L.V., Mayo M.W., Reuther J.Y., Baldwin A.S. Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38. J. Biol. Chem. 2001, 276:18934-18940.
54. Binion D.G., Heidemann J., Li M.S., Nelson V.M., Otterson M.F., Rafiee P. Vascular cell adhesion molecule-1 expression in human intestinal microvascular endothelial cells is regulated by PI 3-kinase/Akt/MAPK/NF-kappaB: inhibitory role of curcumin. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 297:G259-G268.
55. Kefaloyianni E., Gaitanaki C., Beis I. ERK1/2 and p38-MAPK signalling pathways, through MSK1, are involved in NF-kappaB transactivation during oxidative stress in skeletal myoblasts. Cell. Signal. 2006, 18:2238-2251.
56. Gehani S.S., Agrawal-Singh S., Dietrich N., Christophersen N.S., Helin K., Hansen K. Polycomb group protein displacement and gene activation through MSK-dependent H3K27me3S28 phosphorylation. Mol. Cell 2010, 39:886-900.
57. Viatour P., Merville M.P., Bours V., Chariot A. Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem. Sci. 2005, 30:43-52.
58. Obata K., Noguchi K. MAPK activation in nociceptive neurons and pain hypersensitivity. Life Sci. 2004, 74:2643-2653.
59. Daulhac L., Mallet C., Courteix C., Etienne M., Duroux E., Privat A.M., Eschalier A., Fialip J. Diabetes-induced mechanical hyperalgesia involves spinal mitogen-activated protein kinase activation in neurons and microglia via N-methyl-D-aspartate-dependent mechanisms. Mol. Pharmacol. 2006, 70:1246-1254.
60. Bruchas M.R., Yang T., Schreiber S., Defino M., Kwan S.C., Li S., Chavkin C. Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase. J. Biol. Chem. 2007, 282:29803-29811.